

Identification and characterization of the mediators of the calcification paradox

Citation for published version (APA):

Bhargava, S. (2022). *Identification and characterization of the mediators of the calcification paradox*. [Doctoral Thesis, Maastricht University, RWTH Aachen University]. Maastricht University / RWTH Aachen. <https://doi.org/10.26481/dis.20220321sb>

Document status and date:

Published: 01/01/2022

DOI:

[10.26481/dis.20220321sb](https://doi.org/10.26481/dis.20220321sb)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

6. SUMMARY

This thesis focuses on the identification and characterization of novel inhibitors of the pathophysiological process of vascular calcification (VC).

By characterization of CBF, the conditions and concentrations under which this peptide inhibits VC was identified. In addition, we show that this peptide inhibits calcification by hindering transdifferentiation of SMCs by interacting with PIT-1 to inhibit the activation of NF- κ B and its downstream BMP2/p-SMAD pathway, effectively reducing the expression of osteogenic genes and inhibiting apoptosis while promoting metabolism.

Next, CBF (1-8), a small fragment of CBF, was identified which is a more potent inhibitor of medial vascular calcification compared to CBF. The impact of CBF (1-8) on VC was demonstrated and the mechanisms by which CBF (1-8) inhibits VC were illustrated in this thesis. CBF (1-8) reduces apoptosis and promotes cellular metabolism and wound healing thereby reducing VC. In addition, it prevents VC by reducing the transdifferentiation of SMCs to osteoblast-like cells by reducing the expression of osteogenic genes via the BMP2 and β -catenin pathways.

Moreover, CBF (1-8) reverses the loss of bone density caused by VC inducing conditions in VDN rats. The effect of CBF (1-8) on bone density is validated by the absence of any significant difference in enamel and dentine of these animals as they are not actively remodelled, demonstrating that CBF (1-8) promotes mineralization in the actively remodelled bones such as the tibia and the cementum in the dentures.

CBF (1-8) is derived from the protein chromogranin A and might be on of the missing link in our current knowledge about the calcification paradox. Moreover, CBF (1-8) is the first peptidic mediator which links VC to bone mineral density *in vivo*. Understanding the mechanisms by which CBF (1-8) functions, will help utilize the regulatory balance between VC and bone mineralization enabling us to tilt the balance towards bone mineralization by maintaining plasma CBF (1-8) concentration. In addition, the identification and characterization of these previously unknown peptides open novel options for VC therapy without or -at least- limited a negative impact on bone density.

In future, these findings have to be validated in human cohorts for future therapeutic applications. As calcification paradox is a complex process, subsequent investigation of the key factors affecting VC will help to identify specific pathology associated substances affecting bone density. Further, these substances have to be characterized in the context of their impact on bone density using functional bioassays and/or humanized models to find the mechanisms involved.